Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:LITS NASDAQ:MOLN NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.87-0.2%$2.48$1.49▼$4.94$165.31M3.34752,316 shs345,107 shsLITSLite Strategy$1.15+0.4%$1.16$0.95▼$9.00$41.78M0.25335,950 shs182,057 shsMOLNMolecular Partners$4.37+2.7%$4.46$3.41▼$5.36$176.26M1.084,057 shs1,797 shsPRQRProQR Therapeutics$1.69+3.4%$1.68$1.33▼$3.10$178.59M0.08521,435 shs284,159 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+10.38%+6.30%+20.08%+20.08%+71.86%LITSLite Strategy+0.88%0.00%+1.79%+7.55%+113,999,900.00%MOLNMolecular Partners+3.66%+0.94%+5.17%-0.11%+7.75%PRQRProQR Therapeutics+5.16%+10.14%-4.68%+5.16%-9.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$2.87-0.2%$2.48$1.49▼$4.94$165.31M3.34752,316 shs345,107 shsLITSLite Strategy$1.15+0.4%$1.16$0.95▼$9.00$41.78M0.25335,950 shs182,057 shsMOLNMolecular Partners$4.37+2.7%$4.46$3.41▼$5.36$176.26M1.084,057 shs1,797 shsPRQRProQR Therapeutics$1.69+3.4%$1.68$1.33▼$3.10$178.59M0.08521,435 shs284,159 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+10.38%+6.30%+20.08%+20.08%+71.86%LITSLite Strategy+0.88%0.00%+1.79%+7.55%+113,999,900.00%MOLNMolecular Partners+3.66%+0.94%+5.17%-0.11%+7.75%PRQRProQR Therapeutics+5.16%+10.14%-4.68%+5.16%-9.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.70Moderate Buy$10.00249.04% UpsideLITSLite Strategy 1.00SellN/AN/AMOLNMolecular Partners 2.25Hold$8.3891.87% UpsidePRQRProQR Therapeutics 2.63Moderate Buy$7.25330.27% UpsideCurrent Analyst Ratings BreakdownLatest LITS, MOLN, BDTX, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.004/23/2026BDTXBlack Diamond Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026MOLNMolecular Partners HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/21/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026PRQRProQR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026MOLNMolecular Partners Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026PRQRProQR Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/17/2026BDTXBlack Diamond Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$13.00 ➝ $14.003/16/2026MOLNMolecular Partners TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/16/2026MOLNMolecular Partners HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M2.35$0.56 per share5.12$1.97 per share1.45LITSLite Strategy$65.30M0.64$6.03 per share0.19$4.96 per share0.23MOLNMolecular Partners$5.65M31.20N/AN/A$2.40 per share1.82PRQRProQR Therapeutics$17.99M9.87N/AN/A$0.53 per share3.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M$0.377.80N/AN/AN/A23.19%18.48%5/11/2026 (Estimated)LITSLite Strategy-$15.94M-$1.33N/AN/AN/AN/A-68.86%-67.48%N/AMOLNMolecular Partners-$74.41M-$1.99N/AN/AN/AN/A-60.62%-51.84%5/12/2026 (Estimated)PRQRProQR Therapeutics-$47.73M-$0.46N/AN/AN/A-255.83%-65.89%-31.53%5/14/2026 (Estimated)Latest LITS, MOLN, BDTX, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026MOLNMolecular Partners-$0.38N/AN/AN/AN/AN/A5/14/2026Q1 2026PRQRProQR Therapeutics-$0.15N/AN/AN/A$5.19 millionN/A5/11/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18N/AN/AN/A$25.00 millionN/A3/16/2026Q4 2025BDTXBlack Diamond Therapeutics-$0.18-$0.14+$0.04-$0.27$9.38 millionN/A3/12/2026Q4 2025MOLNMolecular Partners-$0.38-$0.41-$0.03-$0.44N/AN/A3/12/2026Q4 2025PRQRProQR Therapeutics-$0.08-$0.09-$0.01-$0.09$6.12 million$5.53 million2/17/2026Q2 2026LITSLite StrategyN/A-$0.82N/A-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.428.42LITSLite StrategyN/A10.0410.04MOLNMolecular PartnersN/A8.788.79PRQRProQR TherapeuticsN/A3.093.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%LITSLite Strategy52.38%MOLNMolecular Partners26.55%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics5.97%LITSLite Strategy1.60%MOLNMolecular Partners5.93%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million53.87 millionOptionableLITSLite Strategy10036.36 million35.78 millionN/AMOLNMolecular Partners18040.38 million37.98 millionNot OptionablePRQRProQR Therapeutics180105.36 million96.51 millionOptionableLITS, MOLN, BDTX, and PRQR HeadlinesRecent News About These CompaniesProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4 at 8:00 AM | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Down 24.4% in AprilApril 29, 2026 | marketbeat.comProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 26, 2026 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50 Day Moving Average - Should You Sell?April 25, 2026 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS), ProQR (PRQR) and Simulations Plus (SLP)April 10, 2026 | theglobeandmail.comProQR Therapeutics: Waiting On Proof As AX-0810 Data ApproachesApril 10, 2026 | seekingalpha.comProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan CapitalApril 9, 2026 | marketbeat.comAberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQRApril 9, 2026 | marketbeat.comProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventApril 8, 2026 | globenewswire.comProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This QuarterApril 8, 2026 | marketbeat.comProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardApril 8, 2026 | globenewswire.comGrowing optimism about ProQR Therapeutics (PRQR)’s RNA editing platform and future clinical catalystsMarch 26, 2026 | msn.comGrowing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical CatalystsMarch 25, 2026 | insidermonkey.comProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026March 25, 2026 | globenewswire.comProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 TranscriptMarch 18, 2026 | seekingalpha.comProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesMarch 12, 2026 | zacks.comProQR Therapeutics N.V.: ProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | finanznachrichten.deProQR Announces Year End 2025 Operating and Financial ResultsMarch 12, 2026 | globenewswire.comProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences ConferenceMarch 3, 2026 | globenewswire.comProQR Announces Planned Changes to Board CompositionFebruary 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLITS, MOLN, BDTX, and PRQR Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$2.86 -0.01 (-0.17%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Lite Strategy NASDAQ:LITS$1.14 +0.01 (+0.44%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Molecular Partners NASDAQ:MOLN$4.36 +0.12 (+2.71%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.ProQR Therapeutics NASDAQ:PRQR$1.68 +0.06 (+3.37%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
